{"id":25074,"date":"2016-08-15T19:35:36","date_gmt":"2016-08-15T19:35:36","guid":{"rendered":"https:\/\/web.uri.edu\/pharmacy\/?page_id=25074"},"modified":"2019-01-17T16:00:36","modified_gmt":"2019-01-17T21:00:36","slug":"model3","status":"publish","type":"page","link":"https:\/\/web.uri.edu\/pharmacy\/research\/rosenbaum\/sims\/model3\/","title":{"rendered":"Model 3: Hepatic Clearance Model"},"content":{"rendered":"
\"support\"<\/div>

Hepatic clearance, or the ability of the liver to extract and metabolize a drug as it passes through the liver, is controlled by hepatic blood flow (Q), protein binding (fu) and the intrinsic ability of the liver enzymes to metabolize a drug (Clint). The relationship between these factors depends on whether a drug is highly or poorly extracted by the liver. This model demonstrates these relationships for high, low and intermediate extraction drugs. The model also demonstrates how hepatic bioavailability is controlled by these factors.<\/h2><\/div><\/div>
View Model<\/div><\/a><\/div>\n

See Chapter 5: Drug Elimination and Clearance
\nTopics relevant to this model are covered in the following sections:<\/h4>\n

\u2013 5.4.7.1 Hepatic Clearance and the Well Stirred Venous Equilibrium Model
\n\u2013 5.4.7.2 Hepatic Bioavailability
\n\u2013 5.4.7.3 Hepatic Oral Clearance
\n\u2013 5.4.7.4 Sensitivity to Changes in Q, Clint, fu<\/p>\n

* High Extraction: Nonrestrictive Clearance
\n* Low Extraction: Restrictive Clearance
\n* Drugs with Mid-Range Extraction Ratios<\/p>\n

\u2013 5.4.7.5 Simulation Model For Hepatic Clearance<\/p>\n

 <\/p>\n